Skip to main content
Mario Lacouture, MD, Dermatology, New York, NY, Memorial Sloan Kettering Cancer Center

MarioLacoutureMD

Dermatology New York, NY

Member, Memorial Hospital, Memorial Sloan Kettering Cancer Center

Dr. Lacouture is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Lacouture's full profile

Already have an account?

Summary

  • I am a board-certified dermatologist with special interest in dermatologic conditions that result from cancer treatments. My clinical career has been focused on the recognition and management of side effects affecting the skin, hair, and nails of cancer patients and survivors. These effects can occur as a consequence of chemotherapy, radiation therapy, or therapeutic transplants.

    Read less
    To ensure that dermatologic side effects do not affect quality of life and the consistent administration of anticancer therapies, I founded the SERIES (Skin and Eye Reactions to Inhibitors of EGFR and kinases) Clinic, an interdisciplinary effort comprising patient care, education, and research. This clinical program is unique in that it provides pre-treatment counseling and preventive efforts in order to minimize the development of side effects, as well as rapid attention to those patients who develop them. Close communication with treating oncologists ensures that interventions against side effects do not affect the effectiveness of cancer treatments. In summary, the ultimate goal is to ensure the best dermatology-related quality of life and benefit from anticancer treatments.

    My research focuses on major components of dermatologic side effects: the accurate description and severity grading; the effects on quality of life; the identification of factors that place individuals at higher risk; and the development of treatments. A basic tenet of this research is in exploring new skin treatments that do not affect the effectiveness of anticancer drugs. For example, we use topical medicines in the face or regional cooling of hands or feet to prevent or treat drug-induced side effects in these areas. A new field being investigated is on dermatologic effects of cancer therapies in long-term cancer survivors, the first step towards ensuring long-term skin health after antineoplastic therapy.

Education & Training

  • University of Chicago
    University of ChicagoResidency, Dermatology, 2002 - 2005
  • Cleveland Clinic Foundation
    Cleveland Clinic FoundationInternship, Transitional Year, 2001 - 2002
  • Brigham and Women's Hospital
    Brigham and Women's HospitalRheumatology & Immunology, 1998 - 2001
  • Pontifical Xavierian University
    Pontifical Xavierian UniversityClass of 1997

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2022 - Present
  • CA State Medical License
    CA State Medical License 2004 - Present
  • NY State Medical License
    NY State Medical License 2009 - 2024
  • CT State Medical License
    CT State Medical License 2023 - 2024
  • IL State Medical License
    IL State Medical License 2002 - 2011
  • OH State Medical License
    OH State Medical License 2001 - 2002
  • American Board of Dermatology Dermatology

Awards, Honors, & Recognition

  • New York Magazine: Top Doctors Castle Connolly, 2014

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Assessment and Treatment Outcomes of Persistent Radiation-Induced Alopecia in Patients with Cancer  
    Morgan E Freret, Robin H Unger, Kathryn Beal, Suzanne L Wolden, Mario E Lacouture, JAMA Dermatology
  • Efficacy of MEK Inhibition in Patients with Histiocytic Neoplasms  
    Robert J Young, Mario Lacouture, Neal Rosen, David M Hyman, Raajit Rampal, Gary A Ulaner, Benjamin H Durham, Lynn A Brody, Nature

Books/Book Chapters

Lectures

  • Safety, tolerability, and PK of topical calcitriol formulation for treatment of chemotherapy-induced alopecia (CIA) in patients receiving taxane-based regimen: Final r... 
    ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
  • Dermatologic Side Effects of Anticancer Drugs in 2019: What You Need to Know 
    American Academy of Dermatology - Annual Meeting 2019 - Washington, D.C. - 3/4/2019

Other

Authored Content

  • Assessment and Treatment Outcomes of Persistent Radiation-Induced Alopecia in Patients with CancerAugust 2020

Press Mentions

  • NanOlogy Publishes Results from a Phase 1/2 Clinical Trial of Its Topical Investigational Drug in the Treatment of Cutaneous Metastases of Breast Cancer
    NanOlogy Publishes Results from a Phase 1/2 Clinical Trial of Its Topical Investigational Drug in the Treatment of Cutaneous Metastases of Breast CancerMay 3rd, 2022
  • Novel BRAF-Inhibitor Cream Ameliorates Rash from EGFR Inhibitors
    Novel BRAF-Inhibitor Cream Ameliorates Rash from EGFR InhibitorsApril 29th, 2021
  • Kintara Therapeutics Appoints Dr. Mario Lacouture to Scientific Advisory Board for Cutaneous Metastatic Breast Cancer
    Kintara Therapeutics Appoints Dr. Mario Lacouture to Scientific Advisory Board for Cutaneous Metastatic Breast CancerMarch 3rd, 2021
  • Join now to see all

Professional Memberships

Other Languages

  • Spanish

Hospital Affiliations